4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-26-059883
Chief Scientific Officer sold 8,500 shares at an average $29.02 ($246,655)
- Chief Scientific Officer acquired 6,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bredt David Chief Scientific Officer | 2026-02-17 | Sale 10b5-1 | −900 | $28.02 | $25,219 | 394,675 | D |
| Bredt David Chief Scientific Officer | 2026-02-17 | Sale 10b5-1 | −5,400 | $28.95 | $156,328 | 389,275 | D |
| Bredt David Chief Scientific Officer | 2026-02-17 | Sale 10b5-1 | −2,200 | $29.59 | $65,108 | 387,075 | D |
| Bredt David Chief Scientific Officer | 2026-02-19 | Option exercise 10b5-1 | +6,000 | $1.80 | $10,800 | 393,075 | D |
| Derivatives | |||||||
| Bredt David Chief Scientific Officer | 2026-02-19 | Option exercise · Stock Options (Right to Buy) 10b5-1 | −6,000 | 88,080 | D | ||
| Open-market sales · 8,500 sh · avg $29.02 · $246,655 | |||||||
Loading xslF345X05/ownership.xml…